Navigation Links
Sanofi-aventis Stands Behind the Safety of Lantus(R)
Date:6/26/2009

BRIDGEWATER, N.J., June 26 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) has just been made aware of data associated with a retrospective follow-up of four patient registries. The results of these data clearly show that no definitive conclusions can be drawn regarding a possible causal relationship between Lantus(R) (insulin glargine [rDNA] injection) use and the occurrence of malignancies, as the authors of the study point out.

Clinical studies, which represent the gold standard of evidence, do not indicate an association between insulin glargine and cancer.

"Given the extensive clinical evidence covering over 70,000 patients and the results of post-marketing surveillance arising from 24 million patient-years of experience, sanofi-aventis stands behind the safety of Lantus(R)," said Jean-Pierre Lehner, M.D., Chief Medical Officer. "We consider that the results of these patient registries are not conclusive."

Patient safety is the primary concern of sanofi-aventis. The Group will continue to vigorously monitor the safety of Lantus(R) in close collaboration with regulatory agencies and scientific experts.

About Diabetes

Diabetes is a chronic, widespread condition in which the body does not produce or properly use insulin, the hormone needed to transport glucose (sugar) from the blood into the cells of the body for energy. More than 230 million people worldwide are living with the disease and this number is expected to rise to a staggering 350 million within 20 years. It is estimated that nearly 24 million Americans have diabetes, including an estimated 5.7 million who remain undiagnosed. At the same time, approximately 40 percent of those diagnosed are not achieving the blood sugar control target of HbA1c <7 percent recomme
'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
2. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
3. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
4. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
5. New Safety Regulations Drive Greater Need for Resources and Expertise at Every Stage of Clinical Development
6. Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily
7. AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA
8. Researchers Present Safety and Efficacy Results of 429 Patients Treated With Radiofrequency Ablation for Pre-Cancerous Barretts Esophagus
9. Living Donor Kidney Transplants Using Alemtuzumab Pre-Conditioning and Tacrolimus Monotherapy: Long-Term Safety and Efficacy
10. Results and Additional Analyses From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
11. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014  VentiRx Pharmaceuticals, Inc., a clinical ... and commercialization of novel Toll-like receptor 8 ... Food and Drug Administration (FDA) has granted ... motolimod (VTX-2337) when administered in combination with ... of women with ovarian cancer whose disease ...
(Date:9/2/2014)...   Intrexon Corporation (NYSE: XON ... it has entered into an Exclusive Channel Collaboration (ECC) ... (EURONEXT: SAN and NYSE: SNY ) to ... of its marketed Active Pharmaceutical Ingredients (APIs) through Sanofi,s ... This collaboration will leverage Intrexon,s proprietary technology suite plus ...
(Date:9/2/2014)... , Sept. 2, 2014   Veracyte, Inc. (Nasdaq: ... Anderson , president and chief executive officer, will present in ... Healthcare Unplugged Conference 2014 on Monday, September 8, 2014 at ... The live audio webcast and subsequent replay may ... Please connect to the website at least 15 minutes prior ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 2VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 3Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 2Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 3Veracyte to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2014 2
... YORK, Sept. 1, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0559262/Global-CRO-Market-Quantitative-Assessment.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development This ... globally, by phase and market type, R&D ...
... This evening, Novo Nordisk awarded sponsorships totaling ... that educate people living with type 2 diabetes on ... risk of long-term diabetes related complications. The sponsorships are ... aims to promote enduring, sustainable change for people living ...
Cached Medicine Technology:Global CRO Market: Quantitative Assessment 2Global CRO Market: Quantitative Assessment 3Novo Nordisk Partners with Minneapolis Community Groups to Support Diabetes Education Programs 2
(Date:9/2/2014)... 02, 2014 West Hollywood cosmetic ... consultations for Invisalign. This special offer includes a free ... to determine their candidacy for the procedure and answer ... patients may also be eligible for the Summer Invisalign ... of the month of August, patients who choose Invisalign ...
(Date:9/2/2014)... MONDAY, Sept. 1, 2014 (HealthDay News) -- The quality ... overall, and dietary disparity between the rich and poor ... provides the most direct evidence to date that the ... U.S. dietary quality are having some payoff, but it ... study author Dong Wang, a doctoral student in the ...
(Date:9/2/2014)... 2, 2014 (HealthDay News) -- When it comes to excess ... equal, a new study finds. The research found that ... person,s odds for high blood pressure more than overall body ... of high blood pressure. But it wasn,t clear how the ... to researchers at University of Texas Southwestern Medical Center in ...
(Date:9/2/2014)... Dallas, Texas (PRWEB) September 02, 2014 ... , “North America Resectoscopes Market Outlook to 2020? ... Resectoscopes market. The report provides value, in millions ... prices (in US dollars) within market segments –, ... Electrodes (Monopolar (Disposable and Reusable) Electrodes and Bipolar ...
(Date:9/2/2014)... USARAD Holdings Inc. a leading ... provider, including SecondOpinions.com® – consumer division is gaining ... services. The telemedicine industry pioneer is now partnering ... Founded and established in 1963 as the first ... as a maternity care hospital with very few ...
Breaking Medicine News(10 mins):Health News:West Hollywood Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Complimentary Consultations for Invisalign 2Health News:Quality of U.S. Diet Improves, Slightly 2Health News:'Spare Tire' May Be Especially Bad for Your Blood Pressure 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 3Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 4Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 2Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 3Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 4
... blockbuster drug and greater reimbursement levels for the treatment ... smoking cessation and addiction treatments are expected to ... 2005 to more than $2.3 billion in 2010, according ... Analysis, a new study released today from Kalorama Information. ...
... a computer based test that may reveal how easily an ... that her scientific test can be used as another ... in fields where employee distraction can lead to fatal errors. ... liable to do things like put your keys in the ...
... are hopeful that the actress' current rehab spell will bring ... wacky recent incidents . ,As the Mean Girls ... on May 28, after being arrested for DUI, her supposed ... ,One friend told America's Star magazine that Lohan ...
... of Illinois dentists provide oral cancer examinations for their ... thoroughly or at optimum intervals, according to a new ... of pre-malignant lesions and of proper examination techniques, some ... be doing to detect oral cancers in their patients," ...
... on Thursday announced that FDA has granted a standard ... Cervarix, Reuters reports. A GSK spokesperson on Thursday said ... been completed in six months. ,Cervarix and ... 100% effective in preventing infection with HPV strains 16 ...
... Dey, L.P. announced today that the U.S. Food ... Drug Application (NDA) of its marketing partner, Critical ... tablets. ZYFLO CR(TM) offers twice-daily, extended-release dosing. Under ... in March 2007, DEY will co-market Critical Therapeutics' ...
Cached Medicine News:Health News:Individuals Distraction can Be Measured by a Computer Based Test 2Health News:Dentists Need More Training in Oral Cancer Detection 2Health News:Dentists Need More Training in Oral Cancer Detection 3Health News:FDA Approves ZYFLO CR(TM) (Zileuton) for Chronic Treatment of Asthma 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: